Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Rhea-AI Summary

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q3 2025 results and a business update on Nov 4, 2025. Key items: 52-week durable symptom and tissue responses observed after a single EP-104GI treatment (two-thirds of Cohort 5, N=3 remained in remission at 1 year).

The company closed an $80.5 million public offering (14,636,363 shares at $5.50) and held $89.0 million cash as of Sept 30, 2025, with a stated runway into the first half of 2028. Topline Phase 2b RESOLVE data expected by Q3 2026.

Operational notes: net loss of $6.4M for Q3 2025; management is monitoring potential impacts from proposed U.S.-Canada tariffs on supply chain and costs.

Positive

• $80.5M public offering closed (14,636,363 shares at $5.50)
• $89.0M cash on hand as of Sept 30, 2025
• Cash runway funded into the first half of 2028
• Durable 52-week clinical responses: two-thirds of Cohort 5 (N=3) in remission
• Topline Phase 2b RESOLVE data expected Q3 2026

Negative

• Phase 1b/2a 52-week result cohort size small: Cohort 5 = N=3
• Net loss of $6.4M in Q3 2025
• Potential operational risk from proposed U.S.-Canada tariffs

News Market Reaction

-10.51% 5.5x vol

2 alerts

-10.51% News Effect

+9.3% Peak Tracked

-$34M Valuation Impact

$287M Market Cap

5.5x Rel. Volume

On the day this news was published, EPRX declined 10.51%, reflecting a significant negative market reaction. Argus tracked a peak move of +9.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $34M from the company's valuation, bringing the market cap to $287M at that time. Trading volume was exceptionally heavy at 5.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI

Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026

Completed $80.5 million public offering supported by leading life science investors

Cash runway to fund pipeline development and operations into the first half of 2028

VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today announced its financial results for the third quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

“The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE),” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

Recent Operational and Financial Highlights

Positive 52-Week Data from Phase 1b/2a RESOLVE Trial: On September 2, 2025, the Company announced the first set of 1-year clinical results from the RESOLVE Trial showing that two-thirds of Cohort 5 patients (N=3) remained in clinical remission after treatment with EP-104GI. Results demonstrated durable symptom and tissue responses beyond nine months of therapy, supporting long-term disease control. Additional 52-week data from cohort 6 is expected later this year.

Closing of $80.5 Million Public Offering: On September 24, 2025, the Company announced the closing of a public offering of Commons Shares (the “Offering”). The Company issued 14,636,363 Common Shares at a price of $5.50 per Common Share for gross proceeds of approximately $80.5 million which included the issuance of 1,909,090 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters. Proceeds will support clinical development of EP-104GI and broader pipeline advancement.

Third Quarter 2025 Financial Review

The Company incurred a net loss of $6.4 million for the three months ended September 30, 2025, versus a net loss of $6.0 million for the three months ended September 30, 2024. The increase in net loss was primarily due to an increase in research and development costs and general and administrative costs, partially offset by an increase in other income.

The Company had cash of $89.0 million as of September 30, 2025, up from $33.1 million at the end of the fourth quarter of 2024. These funds are being used to fund clinical trials in EP-104 and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes.

The Company anticipates that existing cash reserves, and proceeds from the anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the first half of 2028.

As of September 30, 2025, the Company had 50,598,331 common shares and 8,905,638 preferred shares outstanding.

Potential Impact of Tariffs

Management continues to monitor the North American trade situation stemming from the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods.

Eupraxia manufactures its clinical supplies of EP-104IAR and EP-104GI in the U.S. by a third-party. The Company expects to continue to access manufactured products from the U.S.

The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.

Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia's business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.

Financial Statements and Management Discussion & Analysis

Please see the unaudited interim consolidated financial statements and related MD&A for more details. The unaudited interim consolidated financial statements for the quarter ended September 30, 2025, and related MD&A have been reviewed and approved by Eupraxia's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at sedarplus.ca and which is also available on the Company's website at www.eupraxiapharma.com.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected cash runway to fund pipeline development and operations into the first half of 2028; the use of proceeds from the US$80.5 million public offering; the anticipated proceeds from future exercise of in-the-money warrants; the Company’s expectation that it will continue to access manufactured products from the U.S.; the potential imposition of a new reciprocal tariff rate; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company’s product candidates; the results gathered from studies and trials of Eupraxia's product candidates and the timing of the release thereof; the potential for the Company’s technology to impact the drug delivery process; potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

FAQ

What did Eupraxia (EPRX) report for Q3 2025 net loss?

Eupraxia reported a $6.4 million net loss for Q3 2025.

How much cash did EPRX have on Sept 30, 2025 and how long will it fund operations?

Eupraxia had $89.0 million cash and expects runway into the first half of 2028.

What were the terms of Eupraxia's September 2025 public offering (EPRX)?

The company issued 14,636,363 common shares at $5.50 per share for gross proceeds of about $80.5 million.

What clinical progress did EPRX announce for EP-104GI on Nov 4, 2025?

Eupraxia reported durable symptom and tissue responses to 52 weeks; two-thirds of Cohort 5 (N=3) remained in clinical remission after one treatment.

When does EPRX expect topline Phase 2b RESOLVE data for EP-104GI?

Topline data from the Phase 2b RESOLVE Trial is expected in Q3 2026.

Could proposed U.S.-Canada tariffs affect Eupraxia (EPRX)?

Management says it is monitoring proposed tariffs and assessing potential direct and indirect impacts on manufacturing and costs.